

### Colorectal Cancer (CRC) (update) Committee meeting 2

**Date:** 8<sup>th</sup> January 2018

**Location:** RCOG, London

**Minutes:** Confirmed

<b>Committee members present:</b>	
Peter Hoskin, Chair ( <b>PH</b> )	(Present for notes 1– 9)
Justin Davies ( <b>JD</b> )	(Present for notes 1– 9)
Stephen Fenwick ( <b>SF</b> )	(Present for notes 1– 9)
Gemma Burgess ( <b>GB</b> )	(Present for notes 1– 9)
Julie Hepburn ( <b>JH</b> )	(Present for notes 1– 9)
Kevin Monahan ( <b>KM</b> )	(Present for notes 1– 9)
Baljit Singh ( <b>BS</b> )	(Present for notes 1– 9)
Richard Roope ( <b>RR</b> )	(Present for notes 1– 9)
Vivek Misra ( <b>VM</b> )	(Present for notes 1– 9)
Jay Bradbury ( <b>JB</b> )	(Present for notes 1– 9)
Charlotte Dawson ( <b>CD</b> )	(Present for notes 1– 9)

#### 4.0.03 DOC Cmte minutes

<b>In attendance:</b>		
Justine Karpusheff ( <b>JK</b> )	NICE Guidelines Commissioning Manager	(Present for notes 1–7)
Erin Whittingham ( <b>EW</b> )	NICE PIP Lead	(Present for notes 1-6)
Matthew Prettyjohns ( <b>MP</b> )	NGA Guideline Lead	(Present for notes 6–9)
Michaela Dijmarescu ( <b>MD</b> )	NGA Project Manager	(Present for notes 1–9)
Maija Kalioinen ( <b>MK</b> )	NGA Systematic Reviewer	(Present for notes 1–9)
Nathan Bromham ( <b>NB</b> )	NGA Senior Systematic Reviewer	(Present for notes 6 - 8)
Audrey Tan ( <b>AT</b> )	NGA Systematic Reviewer	(Present for notes 1–9)
Sabine Berendse ( <b>SB</b> )	NGA Information Scientist	(Present for notes 3–9)
John Graham ( <b>JG</b> )	NGA Clinical Advisor	(Present for notes 1–9)

<b>Observers:</b>	
Nuala Flewett	NGA Project Manager

<b>Apologies:</b>	
Debby Lennard ( <b>DL</b> )	Lay member

#### **1. Welcome and objectives for the meeting**

The Chair welcomed the committee members to the second meeting for the colorectal cancer (CRC) guideline update.

The Chair informed the Committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included:

- Review 1.1 and recommendations drafting by the committee;
- Developing 4 protocols for review questions 3.6, 4.3, 5.2 and 5.3;

The minutes of the first colorectal cancer guideline committee meeting were confirmed with the committee.

#### 4.0.03 DOC Cmte minutes

The Chair led round the table introductions for the group. A new committee member joined the group (CD).

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests.

There was one declaration of interest included in the table below.

Name	Job title, organisation	Declarations of Interest	Type of interest	Decision taken
Charlotte Dawson	Voluntary sector rep/ Colorectal Clinical Nurse Specialist	Committee member of the Association of Coloproctology Nurse Group.  [10/01/2018]	Personal, non-financial, specific	Declare and participate

During the committee meeting, the order of the items on the agenda was changed as follows:

Item 1. Welcome, housekeeping, aims of the day, apologies, declarations of interest and minutes of the previous committee meeting.

Item 2. NICE Public Involvement

Item 3. Develop protocols for review 3.6.

Item 4. Develop protocols for review 5.2.

Item 5. Develop protocols for review 5.3.

Item 6. GRADE presentation

Item 7. Review 1.1 How effective is aspirin in the prevention of colorectal cancer in adults with clinical or genetic evidence of Lynch syndrome (hereditary nonpolyposis colorectal cancer)? Draft recommendations.

Item 8. Develop protocols for review 4.3.

Item 9. AOB and Close of meeting.

The Economic Priorities presentation was postponed for guideline committee 3, on the 22<sup>nd</sup> February 2018.

#### 4.0.03 DOC Cmte minutes

The minutes of the meeting reflect the order of the items above.
<b>2. NICE Public Involvement</b>
The Chair introduced EW who presented to the committee about patient and carer involvement in guideline development.
<b>3. Develop protocols for review question 3.6. What is the optimal surgical technique for rectal cancer after preoperative radiotherapy and chemotherapy?</b>
The Chair introduced MK (NGA Systematic Reviewer) who presented the protocol for review question 3.6 and finalised it with the committee.
<b>4. Develop protocol for review question 5.2. What is the optimal management of low anterior resection syndrome?</b>
The Chair introduced AT (NGA Systematic Reviewer) who presented the protocol for review question 5.2 and finalised it with the committee.
<b>5. Develop protocol for review question 5.3. What are the information needs of people prior, during and after treatment for colorectal cancer?</b>
The Chair introduced AT (NGA Systematic Reviewer) who presented the protocol for review question 5.3 and finalised it with the committee.
<b>6. GRADE presentation</b>
The Chair introduced NB (NGA Senior Systematic Reviewer) who presented to the Committee how the GRADE process takes place and its role in guideline development. NB then took questions from the group.
<b>7. Review 1.1 How effective is aspirin in the prevention of colorectal cancer in adults with clinical or genetic evidence of Lynch syndrome (hereditary nonpolyposis colorectal cancer)?</b>
The Chair introduced MK (NGA Systematic Reviewer) who led the committee through review 1.1, drafted recommendations with the committee and took questions from the committee.
<b>8. Develop protocols for review questions 4.3.</b>
The Chair introduced AT (NGA Systematic Reviewer) who presented the protocol for review question 4.3 and finalised it with the committee.  <b>A decision was made with the committee to not cover the latter part of the review question 4.3.d as shown below:</b>

#### 4.0.03 DOC Cmte minutes

**Qs 4.3** (split into 4 different questions for protocol development purpose):

a. What is the optimal combination and sequence of local and systemic treatments in patients presenting with oligometastatic colorectal cancer in the lung?

b. What is the optimal combination and sequence of local, loco-regional and systemic treatments in patients presenting with oligometastatic colorectal cancer in the liver?

c. What is the optimal combination and sequence of local and systemic treatments in patients presenting with isolated metastatic colorectal cancer in the peritoneum?

*d. What is the optimal combination and sequence of local and systemic treatments in patients presenting with oligometastatic colorectal cancer in the lymph nodes? (question will not be covered in the guideline).*

#### **9. Any other business**

No other business was discussed.

#### **Close of meeting**

The Chair reminded the Committee that the next meeting would be held on the 22<sup>nd</sup> February 2018 at the RCOG, London and closed the second guideline committee meeting for the NICE Colorectal Cancer (update) guideline.

**Date of next meeting:** 22<sup>nd</sup> February 2018

**Location of next meeting:** RCOG, London